Impact of CES1 Genotype on Metabolism of Methylphenidate

Bispebjerg Hospital

Status and phase: Completed; Phase 4

Conditions: CES1 Activity; Carboxylesterase 1 (CES1) Genotype

Treatments: Drug: Methylphenidate

Study type: Interventional

Funder types: Other

Identifiers

NCT02147535

INDICES-WP2-2

Details and patient eligibility

About

The purpose of this study is to determine whether differences in the gene coding for the liver enzyme carboxylesterase 1 (CES1) means differences in the metabolism of methylphenidate, a CES1 dependent drug.

Enrollment: 78 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• > 18 years old
• Caucasian

Exclusion criteria

• Chronic disease (except hay fever and eczema)
• Pregnancy
• Smoking
• High level of alcohol consumption (> 21 units per week for men and 14 for women)
• Known allergy towards methylphenidate
• Permanent use of medication (contraception ok)

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

78 participants in 1 patient group

Methylphenidate

Experimental group

Treatment:

Drug: Methylphenidate